Navigation Links
Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Date:4/24/2012

DURHAM, N.C., April 24, 2012 /PRNewswire/ -- Argos Therapeutics Inc. today announced that it has secured a $25 million Series D financing to support the commencement of its Phase 3 ADAPT study in patients with newly diagnosed, metastatic renal cell carcinoma (mRCC) in mid-2012. The financing was led by Forbion Capital and included other existing investors, including TVM Capital, Lumira Capital, Intersouth Partners, Caisse de depot et placement du Quebec, Morningside Group, and Aurora Funds. Argos's Arcelis™ immunotherapy, AGS-003, has also been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with mRCC.  The international Phase 3 ADAPT study is expected to commence in mid-2012 under a revised Special Protocol Assessment (SPA) agreement with the FDA. This pivotal study will evaluate the addition of AGS-003 to standard therapy versus standard therapy alone.

"With this latest round of financing Argos is well positioned to execute its business strategy and move forward with the planned Phase 3 ADAPT study of its lead product candidate, AGS-003," said Jeff Abbey, president and chief executive officer of Argos. "We recently presented updated results at the 2012 ASCO Genitourinary Cancers Symposium from a Phase 2 study of AGS-003 demonstrating prolonged survival in newly diagnosed, metastatic RCC patients.  Importantly, we also demonstrated that our intended mechanism of action, the induction of memory T cells, significantly correlated with improved overall survival.  The Phase 3 ADAPT study is designed to confirm these positive results and demonstrate that AGS-003 may be an effective, safe and readily combinable therapeutic option for patients with metastatic RCC."

Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development of Argos, said, "The Fast Track designation by the FDA recogniz
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
2. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
3. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
4. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
5. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
6. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
7. Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
8. Argos Therapeutics Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... SHENZHEN , Chine, 3 juillet 2015 ... séquençage à haut débit de l,ADN situé à ... la certification de  l,American College of Pathologists  (Collège ... BGI à Hong Kong ... nouvelle génération à recevoir la certification du CAP ...
(Date:7/2/2015)... and VANCOUVER , July 2, 2015 ... EPI) announced today that its common shares have been approved ... under the symbol "EPIX". ESSA will begin trading ... its listing on the TSX Venture Exchange under the symbol ... the common shares on the NASDAQ, each of the Company,s ...
(Date:7/2/2015)... July 2, 2015  New product launches are critical ... role in educating thought leaders about new products, Medical ... influence how well a new therapy performs at launch. ... research and consulting leader Best Practices, LLC, critical aspects ... focus on are early stage thought leader (TL) interaction, ...
Breaking Medicine Technology:BGI obtient la certification du Collège des pathologistes américains (CAP) 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2
... DALLAS, April 4, 2008 Data from five ... presented at the National Kidney,Foundation (NKF) 2008 Spring ... utilization studies involve PROCRIT(R) (Epoetin alfa)., The ... and,costs of PROCRIT (EPO) and darbepoetin alfa (DARB), ...
... Previously-Stated Guidance Remains Unchanged, PRINCETON, N.J., ... MEDX ) today issued the following statement ... that it was discontinuing its Phase 3 ... anti-CTLA-4,antibody (tremelimumab) compared to chemotherapy in patients ...
Cached Medicine Technology:Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 2Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 5Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 6Medarex Announces Ipilimumab Program Continues to Move Forward 2Medarex Announces Ipilimumab Program Continues to Move Forward 3Medarex Announces Ipilimumab Program Continues to Move Forward 4Medarex Announces Ipilimumab Program Continues to Move Forward 5
(Date:7/3/2015)... ... July 03, 2015 , ... Smoothies are all the rage right now and ... accessible, quality ingredients. Aurora Natural is proud to introduce a new line of all ... protein, antioxidants, vitamins and minerals! , Aurora is offering a variety of blends and ...
(Date:7/3/2015)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... biblical truth and expose popular lies regarding proper relationships according to the bible. ... goes into the core of the subject by explaining why certain types of sexual ...
(Date:7/2/2015)... ... 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of ... located in the Lone Star State. The premium frozen yogurt chain was listed as ... store, which opened July 1 at Duke’s Travel Plaza, is located at:, 30176 Hwy ...
(Date:7/2/2015)... ... July 02, 2015 , ... With summer in full swing, Americans are flocking to ... of the top spots for fishing in the world, and it’s easy to understand why. ... Canada has great fish. , Recreational fishing is a huge industry, and Americans make ...
(Date:7/2/2015)... ... , ... Global leader and compression innovator, SIGVARIS North America, is ... For style that’s quick on its feet, men will love this fun new way ... everywhere because a simple change in socks can dramatically help improve overall leg health ...
Breaking Medicine News(10 mins):Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3
... Standard" Preventive Medical Exams; New Women,s ... MCKINNEY, Texas, Oct. 18 Signaling the next ... wellness-focused residential,community under development in McKinney, the Cooper ... public. "Father of aerobics" Dr. Kenneth Cooper, who,founded ...
... HR 971 Would Increase the Cost of Prescription ... Care,Management Association (PCMA) issued the following statement in ... hearing on,legislation that would grant independent pharmacists sweeping ... a worse time for policymakers and,consumers alike. As ...
... per cent of psychiatric nurses believe that people with Borderline ... one in fifty adults suffer from the condition, according to ... Health Nursing. , Ninety-eight per cent of nurses said service ... cent said that disagreements between staff on how to care ...
... children under 6, and they may do harm, critics say ... panel of experts at the U.S. Food and Drug Administration ... medicines for young children. , Such a ban already has ... a 365-page review on the issue in late September. Any ...
... in ... women,s health, SAN ... National Association of Nurse,Practitioners in Women,s Health (NPWH) Women,s Health Research ... to the authors of four abstracts to recognize their,outstanding contributions to ...
... announced the,launch of a small group product designed ... UPMC Health Plan,s Small Business Advantage. UPMC,Health Plan ... 99,employees a high- quality, easy-to-implement program of competitive,benefits, ... account manager and customer service team. UPMC ...
Cached Medicine News:Health News:Cooper Clinic at Craig Ranch Opens Signaling the Next Phase of CooperLife Health-Focused Residential Community in McKinney 2Health News:Cooper Clinic at Craig Ranch Opens Signaling the Next Phase of CooperLife Health-Focused Residential Community in McKinney 3Health News:Services for patients with BPD need to be improved say psychiatric nurses 2Health News:Services for patients with BPD need to be improved say psychiatric nurses 3Health News:FDA Panel Weighs Ban on Kids' Cold Medicines 2Health News:FDA Panel Weighs Ban on Kids' Cold Medicines 3Health News:FDA Panel Weighs Ban on Kids' Cold Medicines 4Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 2Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 3Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 4Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 5Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 6Health News:Mission Pharmacal Congratulates Exemplary Women's Health Researchers 7Health News:UPMC Health Plan Launches New Product for Small Businesses 2
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
... latex. Available in even sizes 20-36F. ... maximizing patient comfort., ,The Latex-Free ... maximize patient comfort while offering the ... is economically priced allowing you to ...
Soft red rubber. Adjustable flange. Pediatric sizes available....
Soft Non-Latex, Adjustable Flange Nasopharyngeal Airway. Pediatric sizes available. Non-Latex Mediprene material with soft elastic finish. Adjustable flange for a better fit and increased patient com...
Medicine Products: